Many investors focus on increases in earnings. Perhaps “focus” is the wrong word. It is more like “obsession”. There are commentators that point out, though, that it is not growth in earnings that is important, but return on capital. Growth in earnings achieved by investing below the cost of capital is actually value-destructive.

I would take the idea of ROCE (Return on Capital) one step further: it is not return on capital per se that is important, but return on INCREMENTAL capital. Ideally, what investors want, or at least should want, are high returns on incremental capital, the opportunities to deploy capital at those returns, and a reasonable share price in relation to earnings.

I am growing fonder of Stockopedia’s cashflow statements. They give your 6 year’s worth of data, and it really lays out nicely how cash came in, and where it went.

I think you can also use it to see what a company’s incremental returns have been.

Take a look at spreadbetters IGG (IG Group), for example. For 12 m/e 31-May-2009, it generated operating cashflow of 56.8m. For ye/ 31-May-2014, it was 134.4m. That’s an increase of 77.6m.

The cash used for investing activities during that period was 159.5m (58.1+2.48+25.4+7.14+66.4).

So the return on incremental capital has been around 48.7% (77.6/159.5). That is phenomenal. Revenues have compounded at a rate of 8.9%pa. It pays a generous 4.1% dividend yield. Admittedly, there may be unusual distortions in cashflow there; but still, the company seems to be doing all the right things.

Two other companies that I had thought of as being good-quality companies: DPLM (Diploma) and HLMA (Halma) also, as it turns out, have good incremental returns on capital. DPLM is 22.4%, and HLMA is 16.8%. I think these companies will surprise us positively by the length of their growth. Unfortunately, their valuations are fairly high.

On the other side of the coin, companies that have a high ROCE, but lagging operating cashflows, are AZN (AstraZeneca) and IMT (Imperial Tobacco).

AZN reports that its average ROCE is 21.6%. However, its ROCE starts at 31.0% and ends at 5.9%. Looking at the cashflow statement, I see that it had operating cashflows of $11739m for y/e 31-Dec-2009, decreasing to $7058m for y/e 31-Dec-2014. Cash invested during that period amounted to $11440m. At least so far, AZN has invested a lot of money with little to show for it. The company’s “patent cliff” is well-publicised, and the company seems to…

Unlock the rest of this article with a 14 day trial

Already have an account?
Login here